On Friday, Shares of National-Oilwell Varco, Inc. (NYSE:NOV), lost -1.40% to $49.19.
National-Oilwell Varco, declared that its Board of Directors declared the regular quarterly cash dividend of $0.46 per share of common stock, payable on June 26, 2015 to each stockholder of record on June 12, 2015.
National Oilwell Varco, Inc. designs, manufactures, and sells equipment and components used in oil and gas drilling, completion, and production; and provides oilfield services to the upstream oil and gas industry worldwide.
Shares of Charter Communications, Inc. (NASDAQ:CHTR), inclined 1.51% to $ 179.02, during its last trading session.
Charter Communications, declared that they have reached a definitive agreement for Charter to merge with Time Warner Cable. The deal values Time Warner Cable at $78.7 billion. Charter will provide $100.00 in cash and shares of a new public parent company equivalent to 0.5409 shares of CHTR for each Time Warner Cable share outstanding. The deal values each Time Warner Cable share at about $195.71 based on Charter’s market closing price on May 20, or about $200 based on Charter’s 60-trading day volume weighted average price. In addition, Charter will provide an election option for each Time Warner Cable stockholder, other than Liberty Broadband Corporation or Liberty Interactive Corporation, who will receive all stock, to receive $115.00 of cash and New Charter shares equivalent to 0.4562 shares of CHTR for each Time Warner Cable share they own.
Charter Communications, Inc., through its auxiliaries, provides entertainment, information, and communications solutions to residential and commercial customers in the United States.
At the end of Friday’s trade, Shares of SanDisk Corporation (NASDAQ:SNDK), lost -1.73% to $ 68.38.
SanDisk Corporation, launched two new, USB 3.0 flash drives – the 128GB* SanDisk Ultra Fit™ USB 3.0 Flash Drive, the world’s smallest USB 3.0; and the 256GB SanDisk Ultra® USB 3.0 Flash Drive, SanDisk’s highest capacity USB flash drive to-date. The new offerings enhance SanDisk’s award-winning USB line-up with impressive capacities and performance, delivering speeds up to 10 times faster than a standard USB 2.0 drive1. With these higher capacities, consumers can now save more of their favorite videos, photos and music on their laptops, TVs, gaming consoles or other entertainment systems.
SanDisk Corporation designs, develops, manufactures, and markets data storage solutions in the United States and internationally. The company offers removable cards, which are used in various applications and consumer devices, counting digital cameras, camcorders, smartphones, tablets, and eReaders under the SanDisk Ultra, SanDisk Extreme, and SanDisk Extreme PRO brands; and embedded products that are used in mobile phones, tablets, notebooks, and other portable and wearable devices, in addition to in automotive and connected home applications under the brand name iNAND.
Finally, Amgen, Inc. (NASDAQ:AMGN), ended its last trade with -0.69% loss, and close at $ 156.26.
Amgen, declared the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis for Injection administered once-weekly with dexamethasone as compared to the current U.S. Food and Drug Administration approved twice-weekly administration plan in patients with relapsed and refractory multiple myeloma who have received preceding treatment with bortezomib and an immunomodulatory agent.The trial was initiated based on results from the Phase 1/2 CHAMPION study, which were presented (abstract no. 8527) at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday, May 31 at 8 a.m. CT.
Results from the Phase 1 and 2 portions of CHAMPION were presented for 104 patients (Phase 1, n=15; Phase 2, n=89) with relapsed or refractory multiple myeloma who had received one to three preceding treatment regimens at the determined maximum tolerated dose of 20/70 mg/m2. In the Phase 2 portion of the study, the overall response rate (ORR; defined as the percentage of patients achieving a partial response or better) was 77 percent. The clinical benefit rate (CBR; defined as the percentage of patients with minimal response or better) was 84 percent; the median time to response for patients who achieved a partial response or better was 1.6 months (range, 0.7-7.2); Kaplan-Meier median duration of response (DOR) was 15 months (95 percent CI 9-not estimable); and the Kaplan-Meier median progression-free survival (PFS) was 10.6 months (95 percent CI 9.0-16.1).
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
